Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preliminary evaluation of a neuronavigation-integrated suction device for intracranial infiltrative high-grade glioma resection: A propensity score-matched analysis.

Clinical neurology and neurosurgery·2025
Same author

Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy.

Aging cell·2025
Same author

Indication-based analysis of laser interstitial thermal therapy: a propensity score-matched comparison of outcomes for brain tumor versus epilepsy indications.

Neurosurgical focus·2024
Same author

Utility of combining frailty and comorbid disease indices in predicting outcomes following craniotomy for adult primary brain tumors: A mixed-effects model analysis using the nationwide readmissions database.

Clinical neurology and neurosurgery·2024
Same author

When DNA-damage responses meet innate and adaptive immunity.

Cellular and molecular life sciences : CMLS·2024
Same author

The Influence of Modifiable Risk Factors on Postoperative Outcomes in Patients Receiving Surgery for Resection for Acoustic Neuroma.

Ear, nose, & throat journal·2023

Related Experiment Video

Updated: Jan 1, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.3K

Dendritic cell immunotherapy for malignant gliomas.

Anne Luptrawan1, Gentao Liu, John S Yu

  • 1Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA. anne.luptrawan@cshs.org

Reviews on Recent Clinical Trials
|May 14, 2008
PubMed
Summary

Dendritic cell (DC) immunotherapy shows promise for treating malignant gliomas, a deadly brain cancer. These immune cells can enhance anti-tumor responses and improve chemotherapy effectiveness, offering new hope for patients.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

Related Experiment Videos

Last Updated: Jan 1, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Malignant gliomas, including glioblastoma multiforme, have a poor prognosis despite standard treatments.
  • Tumor infiltration, immune evasion, and chemotherapy resistance contribute to treatment failure.
  • Dendritic cells (DCs) are emerging as a potential therapeutic agent in cancer treatment.

Purpose of the Study:

  • To review clinical trials of dendritic cell-based immunotherapy for malignant gliomas.
  • To explore future strategies for DC vaccines in glioma treatment.

Main Methods:

  • Review of published clinical trial data on dendritic cell immunotherapy for malignant gliomas.
  • Analysis of the mechanisms by which DCs impact anti-tumor immunity and chemotherapy sensitization in gliomas.

Main Results:

  • Dendritic cells have shown potential in promoting anti-tumor immune responses against gliomas.
  • DC-based approaches may sensitize glioma cells to chemotherapy, potentially improving treatment outcomes.
  • Clinical trial results indicate a role for DC immunotherapy in managing malignant gliomas.

Conclusions:

  • Dendritic cell immunotherapy represents a promising strategy for malignant glioma treatment.
  • Further research and clinical trials are needed to optimize DC vaccine strategies for glioma immunotherapy.
  • Combining DC-based approaches with conventional therapies may improve patient prognosis.